Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: Open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 147, Issue 2, 2009, Pages 195-200

  Junge, Wolfgang ^a   El Samalouti, Volker ^a   Gerlinger, Christoph ^b   Schaefers, Matthias ^b  

^a LKF Laboratorium für Klinische Forschung GmbH   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Coronary heart disease; Drospirenone; Hemostasis; Menopausal hormone therapy; Venous thromboembolism

Indexed keywords

D DIMER; DROSPIRENONE PLUS ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; AMENORRHEA; ARTICLE; BLEEDING; BLOOD CLOTTING; BODY WEIGHT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FIBRINOLYSIS; HEART RATE; HEMOSTASIS; HORMONAL THERAPY; HUMAN; ISCHEMIA; LUNG EMBOLISM; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPOTTING; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

EID: 71849111480     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2009.09.004     Document Type: Article

References (32)

1. Nelson H.D. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 291 (2004) 1610-1620
2. Pines A., Sturdee D.W., et al., Board of the International Menopause Society. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 10 (2007) 181-194
3. Grodstein F., and Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 38 (1995) 199-210
4. Grady D., Rubin S.M., Petitti D.B., et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117 (1992) 1016-1037
5. Salpeter S.R., Walsh J.M., Greyber E., Ormiston T.M., and Salpeter E.E. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 19 (2004) 791-804
6. Herrington D.M., Reboussin D.M., Brosnihan K.B., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343 (2000) 522-529
7. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
8. Manson J.E., Hsia J., Johnson K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 (2003) 523-534
9. Hsia J., Langer R.D., Manson J.E., et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 166 (2006) 357-365
10. Grodstein F., Manson J.E., and Stampfer M.J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 15 (2006) 35-44
11. Rossouw J.E., Prentice R.L., Manson J.E., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297 (2007) 1465-1477
12. Manson J.E., Allison M.A., Rossouw J.E., et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 356 (2007) 2591-2602
13. Kooperberg C., Cushman M., Hsia J., et al. Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone Trials. PLoS Clin Trials 2 (2007) e28
14. Rossouw J.E., Cushman M., Greenland P., et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the Women's Health Initiative trials of hormone therapy. Arch Intern Med 168 (2008) 2245-2253
15. Schindler A.E., Campagnoli C., Druckmann R., et al. Classification and pharmacology of progestins. Maturitas 46S1 (2003) S7-S16
16. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 47 (2004) 277-283
17. Fuhrmann U., Krattenmacher R., Slater E.P., and Fritzemeier K.H. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 54 (1996) 243-251
18. Rubig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climacteric 6 Suppl. 3 (2003) 49-54
19. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62 (2000) 29-38
20. White W.B., Hanes V., Chauhan V., and Pitt B. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension 48 (2006) 246-253
21. White W.B., Pitt B., Preston R.A., and Hanes V. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 112 (2005) 1979-1984
22. Preston R.A., Alonso A., Panzitta D., Zhang P., and Karara A.H. Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens 15 (2002) 816-822
23. Preston R.A., Norris P.M., Alonso A.B., Ni P., Hanes V., and Karara A.H. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause 14 (2007) 408-414
24. Wells P.S., Anderson D.R., Rodger M., et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 349 (2003) 1227-1235
25. Scarabin P.Y., Alhenc-Gelas M., Plu-Bureau G., Taisne P., Agher R., and Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 17 (1997) 3071-3078
26. Zegura B., Guzic-Salobir B., Sebestjen M., and Keber I. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause 13 (2006) 643-650
27. Sumino H., Ichikawa S., Sawada Y., et al. Effects of hormone replacement therapy on blood coagulation and fibrinolysis in hypertensive and normotensive postmenopausal women. Thromb Res 115 (2005) 359-366
28. Post M.S., van der Mooren M.J., van Baal W.M., et al. Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study. Am J Obstet Gynecol 189 (2003) 1221-1227
29. Norris L.A., Brosnan J., Bonnar J., Conard J., Kluft C., and Hellgren M. Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/dydrogesterone and estradiol (2 mg)/trimegestone. Thromb Haemost 100 (2008) 253-260
30. Dinger J.C., and Heinemann L.A.J. European active surveillance study of women taking HRT (EURAS-HRT): study protocol [NCT00214903]. BMC Women's Health 6 (2006) 1
31. Archer D.F., Thorneycroft I.H., Foegh M., et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 12 (2005) 716-727
32. Foidart J.M., and Faustmann T. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17α-spirolactone-derived progestogen. Gynecol Endocrinol 23 (2007) 692-699